Trimodality Approach for Esophageal Malignancies - 25/05/21
Doi : 10.1016/j.suc.2021.03.007
Ammara A. Watkins, MD, MPH a, Jessica A. Zerillo, MD, MPH b, Michael S. Kent, MD a, ⁎ 
a Division of Thoracic Surgery and Interventional Pulmonology, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Road, Boston, MA 02215, USA
b Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Shapiro 9, Boston, MA 02215, USA
∗Corresponding author.
Résumé |
Trimodality therapy, or the use of concurrent chemoradiation followed by surgery, is the cornerstone of contemporary management of esophageal cancer. This article discusses the landmark trials and most current data to understand the concepts, applications, and outcomes from trimodality therapy in locally advanced esophageal cancer.
Le texte complet de cet article est disponible en PDF.Keywords : Trimodality therapy, Neoadjuvant, Chemoradiation, Esophageal cancer
Plan
© 2021
Elsevier Inc. Tous droits réservés.
Vol 101 - N° 3
P. 453-465 - juin 2021 Retour au numéro
Article précédent
- Chemoradiation Therapy as Definitive Treatment of Esophageal Cancer
- Sue Xue Wang, M. Blair Marshall
- Salvage Esophagectomy
- Romulo Fajardo, Abbas E. Abbas, Roman V. Petrov, Charles T. Bakhos
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?